Dalqan Real Estate Company K.S.C. (Public) (KWSE:DALQANRE)

CTI BioPharma Cash Flow Statement

Financials in millions KWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	0.7	0.69	0.57	0.18	0.04	0.02
Gain (Loss) on Sale of Assets	-0.48	-0.48	-0.21	-	-	-
Asset Writedown	-0.14	-0.14	-0.29	-	0.13	0.11
Change in Other Net Operating Assets	0.01	-0	0.01	-0.03	0	-0
Other Operating Activities	0.13	0.13	0.09	0	0	0
Operating Cash Flow	0.22	0.2	0.18	0.15	0.17	0.14
Operating Cash Flow Growth	23.44%	9.28%	18.22%	-11.01%	25.22%	-44.77%
Acquisition of Real Estate Assets	-7.14	-5.01	-2.1	-2.06	-	-
Sale of Real Estate Assets	3.79	3.79	0.85	-	-	-
Net Sale / Acq. of Real Estate Assets	-3.35	-1.22	-1.25	-2.06	-	-
Investing Cash Flow	-3.35	-1.22	-1.25	-2.06	-	-
Short-Term Debt Issued	-	3.36	0.88	-	-	-
Long-Term Debt Issued	-	-	-	1.41	-	-
Total Debt Issued	4.82	3.36	0.88	1.41	-	-
Net Debt Issued (Repaid)	4.82	3.36	0.88	1.41	-	-
Repurchase of Common Stock	-	-	-	-0.34	-	-
Common Dividends Paid	-	-0.3	-0.18	-	-	-
Other Financing Activities	-0.12	-0.12	-0.09	-	-	-
Net Cash Flow	1.56	1.91	-0.46	-0.84	0.17	0.14
Levered Free Cash Flow	0.37	0.35	0.2	0.08	0.11	0.08
Unlevered Free Cash Flow	0.48	0.43	0.25	0.08	0.11	0.08
Change in Net Working Capital	-0.01	0	-0.01	0.03	-0	0

Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.